Maintenance treatment with orally etoposide for extensive stage small cell lung cancer: a phase II study

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-TNC-09000357

Enrollment

Unknown

Registered

2009-03-24

Start date

2009-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small cell lung cancer (Extensive stage)

Interventions

Maintenance therapy group:EP regimen: Etoposide 100mg/m2, day 1-4 + Cisplatin 80mg/m2, day1 or divided to 3 days, repeated every 21 days for 4 cycles. Maintenance therapy: Orally Etoposide 50mg/m2, da

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Pathologically proved small cell lung cancer; 2. Extensive stage; 3. Over age of 18; 4. No prior antitumor therapy had been administered; 5. Performance status is of ECOG 0-2; 6. No contraindication to etoposide or cisplatin; 7. Expectation of life was over 12 weeks; 8. Voluntary participation and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Not controlled brain metastasis; 2. Only unevaluable tumor is present; 3. Pregnancy or lactation; 4. Combined with any unstable systemic diseases; 5. Deglutation disorder; 6. Combined with disease of digestive tract that would influence the drug absorption; 7. Abnormal mental state; 8. Patients with poor compliance who are unsuitable for this study.

Design outcomes

Primary

Measure	Time frame
Grade 4 toxicities;Progression free surviva;	—

Secondary

Measure	Time frame
Overall survival;	—

Countries

China

Contacts

Public ContactJiang Zhu

zhujiang1@medmail.com.cn+86 0 13880087086

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026